CTi Biopharma Corp


Prices are adjusted according to historical splits.

CTi Biopharma Corp Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$582.74 million
Book Value:
Revenue TTM:
$53.95 million
Operating Margin TTM:
Gross Profit TTM:
$50.43 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

CTi Biopharma Corp had its IPO on 1997-03-21 under the ticker symbol CTIC.

The company operates in the Healthcare sector and Biotechnology industry. CTi Biopharma Corp has a staff strength of 127 employees.

Stock update

Shares of CTi Biopharma Corp opened at $4.37 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $4.2 - $4.39, and closed at $4.34.

This is a -1.59% slip from the previous day's closing price.

A total volume of 6,475,100 shares were traded at the close of the day’s session.

In the last one week, shares of CTi Biopharma Corp have slipped by -4.41%.

CTi Biopharma Corp's Key Ratios

CTi Biopharma Corp has a market cap of $582.74 million, indicating a price to book ratio of 112.6329 and a price to sales ratio of 22.0081.

In the last 12-months CTi Biopharma Corp’s revenue was $53.95 million with a gross profit of $50.43 million and an EBITDA of $-69336000. The EBITDA ratio measures CTi Biopharma Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CTi Biopharma Corp’s operating margin was -132.14% while its return on assets stood at -44.92% with a return of equity of -1018.75%.

In Q4, CTi Biopharma Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 216.6%.

CTi Biopharma Corp’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 26.5957 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CTi Biopharma Corp’s profitability.

CTi Biopharma Corp stock is trading at a EV to sales ratio of 20.1729 and a EV to EBITDA ratio of -6.6763. Its price to sales ratio in the trailing 12-months stood at 22.0081.

CTi Biopharma Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$125.93 million
Total Liabilities
$81.13 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

CTi Biopharma Corp ended 2023 with $125.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $125.93 million while shareholder equity stood at $-17577000.00.

CTi Biopharma Corp ended 2023 with $0 in deferred long-term liabilities, $81.13 million in other current liabilities, 131000.00 in common stock, $-2518907000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $30.42 million and cash and short-term investments were $79.94 million. The company’s total short-term debt was $47,943,000 while long-term debt stood at $0.

CTi Biopharma Corp’s total current assets stands at $99.40 million while long-term investments were $0 and short-term investments were $49.52 million. Its net receivables were $15.39 million compared to accounts payable of $2.01 million and inventory worth $733000.00.

In 2023, CTi Biopharma Corp's operating cash flow was $537000.00 while its capital expenditure stood at $0.

Comparatively, CTi Biopharma Corp paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

CTi Biopharma Corp stock is currently trading at $4.34 per share. It touched a 52-week high of $7.8 and a 52-week low of $7.8. Analysts tracking the stock have a 12-month average target price of $11.23.

Its 50-day moving average was $5.34 and 200-day moving average was $5.71 The short ratio stood at 5.74 indicating a short percent outstanding of 0%.

Around 18.8% of the company’s stock are held by insiders while 8183.7% are held by institutions.

Frequently Asked Questions About CTi Biopharma Corp

The stock symbol (also called stock or share ticker) of CTi Biopharma Corp is CTIC

The IPO of CTi Biopharma Corp took place on 1997-03-21

Similar Industry Stocks (Biotechnology)

Last Price
US Gold Corp (USAU)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.


3101 Western Avenue, Seattle, WA, United States, 98121